Comparative Pharmacology
Head-to-head clinical analysis: ENOVID E 21 versus OGESTREL 0 5 50 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOVID E 21 versus OGESTREL 0 5 50 21.
ENOVID-E 21 vs OGESTREL 0.5/50-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Norethindrone is a progestin that suppresses gonadotropin release, inhibiting ovulation; mestranol is an estrogen that stabilizes endometrium and provides cycle control.
Combination of norgestrel and ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; alters cervical mucus and endometrial lining.
One tablet (norethynodrel 2.5 mg, mestranol 0.1 mg) orally once daily for 21 consecutive days, followed by 7 days without medication. Repeat cycle.
One tablet (norgestrel 0.5 mg / ethinyl estradiol 0.05 mg) orally once daily for 21 days, followed by 7 placebo days.
None Documented
None Documented
Terminal elimination half-life: 27–36 hours (mean 30.8 h). Steady-state reached after 5–7 days. Clinical context: allows once-daily dosing with stable estrogenic effect.
Norgestrel: 24-32 hours; Ethinyl estradiol: 7-12 hours. Clinical context: Steady state achieved after 5-7 days.
73% renal (45% as unchanged norethindrone, 20% as conjugates, 8% as other metabolites), 27% fecal via bile. Enterohepatic recirculation accounts for 15% of total clearance.
Renal: ~50% (metabolites); Fecal/Biliary: ~50% (metabolites); <1% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive